| Company Name: | PreMD, Incorporated | | Ticker Symbol: | PME | | | WWW Address: | www.premdinc.com | | CEO: | Dr. H.B. Brent Norton, MD, MBA | | No. of Employees: | 11 | | Common Issue Type: | CS | | Business Description: | A medicine company engaged in the improvement of health outcomes with non- or minimally invasive tools for the early detection of life-threatening diseases, particularly cardiovascular disease and cancer.
|
| | | Industry Information: | HEALTH SERVICES - Medical Laboratories & Research [more like this] |
|
| Price | Day Change | Bid | Ask | Open | High | Low | Volume | | 0.0321 |  0.0 | - | - | 0 | 0.04 | 0.03 | - |
| Market Cap (mil) | Shares Outstanding (mil) | Beta | EPS | DPS | P/E | Yield | 52-Wks-Range |
| 0.9 | 26.7 | -1.82 | -0.26 | 0.00 | 0.0 | 0.0 | 1.89 - 0.03 |
|
| KEY FIGURES (Latest Twelve Months - LTM) | | Yesterday's Close | 0.03 | $ | | PE Ratio - LTM | 0.0 | |
| Market Capitalisation | 0.9 | mil |
| Latest Shares Outstanding | 26.7 | mil |
| Earnings pS (EPS) | -0.26 | $ |
| Dividend pS (DPS) | 0.00 | ¢ |
| Dividend Yield | 0.0 | % |
| Dividend Payout Ratio | 0 | % |
| Revenue per Employee | 8,652 | $ |
| Effective Tax Rate | 0.0 | % |
| Float | 0.0 | mil |
| Float as % of Shares Outstanding | 0.0 | % |
| Foreign Sales | 0 | mil |
| Domestic Sales | 0 | mil |
| Selling, General & Adm/tive (SG&A) as % of Revenue | 2,672.80 | % |
| Research & Devlopment (R&D) as % of Revenue | 2,374.60 | % |
| Gross Profit Margin | -23.6 | % |
| EBITDA Margin | 0.0 | % |
| Pre-Tax Profit Margin | 0.0 | % |
| Assets Turnover | 0.0 | % |
| Return on Assets (ROA) | -215.3 | % |
| Return on Equity (ROE) | 0.0 | % |
| Return on Capital Invested (ROCI) | -424.4 | % |
| Current Ratio | 2.3 | |
| Leverage Ratio (Assets/Equity) | 0.0 | |
| Interest Cover | 0.0 | |
| Total Debt/Equity (Gearing Ratio) | 0.00 | |
| LT Debt/Total Capital | 431.0 | % |
| Working Capital pS | 0.05 | $ |
| Cash pS | 0.03 | $ |
| Book-Value pS | 0.00 | $ |
| Tangible Book-Value pS | -0.19 | $ |
| Cash Flow pS | -0.23 | $ |
| Free Cash Flow pS | -0.18 | $ |
 |
| KEY FIGURES (LTM): Price info |
| Price/Book Ratio | 0.00 | |
| Price/Tangible Book Ratio | -0.17 | |
| Price/Cash Flow | -0.1 | |
| Price/Free Cash Flow | -0.2 | |
| P/E as % of Industry Group | 0.0 | % |
| P/E as % of Sector Segment | 0.0 | % |
| | | Balance Sheet (at a glance) in Millions |
| | | | | | DIVIDEND INFO | | Type of Payment | - |
| Dividend Rate | 0.00 |
| Current Dividend Yield | 0.0 |
| 5-Y Average Dividend Yield | 0.0 |
| Payout Ratio | 0.0 |
| 5-Y Average Payout Ratio | 0.0 |
| |
| |
| |
| |
| |
|  | | Share price performance previous 3 years |
|
 | | | Share price performance intraday |
|
 | |
| |
| PRICE/VOLUME | High | Low | Close | % Price Chg | % Price Chg vs. Mkt. | Avg. Daily Vol | Total Vol |
| 1 Week | - | - | - | -50.0 | 50 | 3,186 | 14,353 |
| 4 Weeks | 0.29 | 0.03 | 0.23 | -87.0 | 13 | 1,839 | 33,098 |
| 13 Weeks | 0.38 | 0.03 | 0.15 | -80.0 | 22 | 725 | 44,942 |
| 26 Weeks | 0.50 | 0.03 | 0.26 | -88.5 | 12 | 482 | 60,306 |
| 52 Weeks | 1.89 | 0.03 | 1.60 | -98.1 | 2 | 328 | 81,557 |
| YTD | 1.30 | 0.03 | - | -97.7 | 3 | 433 | 71,805 |
| Moving Average | 5-Days | 10-Days | 10-Weeks | 30-Weeks | 200-Days | Beta (60-Mnth) | Beta (36-Mnth) |
| 0.05 | 0.11 | 0.25 | 0.24 | 0.48 | -1.82 | -3.52 |
|
| |
| GROWTH RATES | 5-Year
Growh | R² of 5-Year Growth | 3-Year
Growth |
| Revenue | 0.00 | 0.0 | -42.02 |
| Income | 0.00 | 0.0 | 0.00 |
| Dividend | 0.00 | 0.0 | 0.00 |
| Capital Spending | -7.64 | NA | -50.51 |
| R&D | 18.93 | NA | 7.59 |
| Normalized Inc. | 0.00 | NA | 0.00 |
| | | CHANGES | YTD vs.
Last YTD | Curr Qtr vs.
Qtr 1-Yr ago | Annual vs.
Last Annual |
| Revenue % | 119.3 | 119.3 | -96.7 |
| Earnings % | 0.0 | 0.0 | 0.0 |
| EPS % | 0.0 | 0.0 | 0.0 |
| EPS $ | -0.01 | -0.01 | -0.03 |
|
| |
| SOLVENCY RATIOS | | SHORT-TERM SOLVENCY RATIOS (LIQUIDITY) |
| Net Working Capital Ratio | 42.82 |
| Current Ratio | 2.0 |
| Quick Ratio (Acid Test) | 1.3 |
| Liquidity Ratio (Cash) | 1.01 |
| Receivables Turnover | 0.4 |
| Average Collection Period | 900 |
| Working Capital/Equity | -26.7 |
| Working Capital pS | 0.05 |
| Cash-Flow pS | -0.25 |
| Free Cash-Flow pS | -0.23 |
| FINANCIAL STRUCTURE RATIOS |
| Altman's Z-Score Ratio | -8.19 |
| Financial Leverage Ratio (Assets/Equity) | 0.0 |
| Debt Ratio | 260.3 |
| Total Debt/Equity (Gearing Ratio) | 0.00 |
| LT Debt/Equity | 0.00 |
| LT Debt/Capital Invested | 497.1 |
| LT Debt/Total Liabilities | 78.4 |
| Interest Cover | 0.0 |
| Interest/Capital Invested | 105.40 |
| | | | VALUATION RATIOS | | MULTIPLES |
| PQ Ratio | 6.29 |
| Tobin's Q Ratio | 0.31 |
| Current P/E Ratio - LTM | 0.00 |
| Enterprise Value (EV)/EBITDA | -1.16 |
| Enterprise Value (EV)/Free Cash Flow | 0.04 |
| Dividend Yield | 0.0 |
| Price/Tangible Book Ratio - LTM | -0.17 |
| Price/Book Ratio - LTM | 0.00 |
| Price/Cash Flow Ratio | -0.1 |
| Price/Free Cash Flow Ratio - LTM | -0.2 |
| Price/Sales Ratio | 0.00 |
| P/E Ratio (1 month ago) - LTM | 0.0 |
| P/E Ratio (26 weeks ago) - LTM | 0.0 |
| P/E Ratio (52 weeks ago) - LTM | 0.0 |
| 5-Y High P/E Ratio | 0.0 |
| 5-Y Low P/E Ratio | 0.0 |
| 5-Y Average P/E Ratio | 0.0 |
| Current P/E Ratio as % of 5-Y Average P/E | 0 |
| P/E as % of Industry Group | 0.0 |
| P/E as % of Sector Segment | 0.0 |
| Current 12 Month Normalized P/E Ratio - LTM | 0.0 |
| PER SHARE FIGURES |
| LT Debt pS | 0.22 |
| Current Liabilities pS | 0.05 |
| Tangible Book Value pS - LTM | -0.19 |
| Book Value pS - LTM | 0.00 |
| Capital Invested pS | 0.05 |
| Cash pS - LTM | 0.03 |
| Cash Flow pS - LTM | -0.23 |
| Free Cash Flow pS - LTM | -0.18 |
| Earnings pS (EPS) | -0.26 |
| | | | OPERATING RATIOS | | PROFITABILITY RATIOS |
| Free Cash Flow Margin | -6,012.82 |
| Free Cash Flow Margin 5YEAR AVG | -1,366.18 |
| Net Profit Margin | 0.0 |
| Net Profit Margin - 5YEAR AVRG. | 0.0 |
| Equity Productivity | -0.02 |
| Return on Equity (ROE) | 0.0 |
| Return on Equity (ROE) - 5YEAR AVRG. | 0.0 |
| Capital Invested Productivity | 0.08 |
| Return on Capital Invested (ROCI) | -523.2 |
| Return on Capital Invested (ROCI) - 5YEAR AVRG. | -126.4 |
| Assets Productivity | 0.00 |
| Return on Assets (ROA) | -229.0 |
| Return on Assets (ROA) - 5YEAR AVRG. | -80.9 |
| Gross Profit Margin | -23.6 |
| Gross Profit Margin - 5YEAR AVRG. | 85.4 |
| EBITDA Margin - LTM | 0.0 |
| EBIT Margin - LTM | 0.0 |
| Pre-Tax Profit Margin | 0.0 |
| Pre-Tax Profit Margin - 5YEAR AVRG. | 0.0 |
| Effective Tax Rate | 0.0 |
| Effective Tax Rate - 5YEAR AVRG. | 0.0 |
| EFFICIENCY RATIOS |
| Cash Conversion Cycle | 1,601 |
| Revenue per Employee | 8,652 |
| Net Income per Employee | -578,126 |
| Average Collection Period | 1,326 |
| Receivables Turnover | 0.4 |
| Day's Inventory Turnover Ratio | 275 |
| Inventory Turnover | 1.3 |
| Inventory/Sales | 64.7 |
| Accounts Payble/Sales | 323.02 |
| Assets/Revenue | 0.00 |
| Net Working Capital Turnover | 0.08 |
| Fixed Assets Turnover | 0.24 |
| Total Assets Turnover | 0.0 |
| Revenue per $ Cash | 0.33 |
| Revenue per $ Plant | 1.01 |
| Revenue per $ Common Equity | -0.02 |
| Revenue per $ Capital Invested | 0.08 |
| Selling, General & Adm/tive (SG&A) as % of Revenue | 3399.4 |
| SG&A Expense as % of Revenue - 5YEAR AVRG. | 270.0 |
| Research & Devlopment (R&D) as % of Revenue | 2938.6 |
| R&D Expense as % of Revenue - 5YEAR AVRG. | 2938.6 |
|
|  
|
| |
 |  |